Provided by Tiger Trade Technology Pte. Ltd.

Maze Therapeutics

26.43
-0.2200-0.83%
Post-market: 26.430.00000.00%19:30 EDT
Volume:633.05K
Turnover:16.89M
Market Cap:1.46B
PE:-10.50
High:27.49
Open:27.08
Low:26.36
Close:26.65
52wk High:53.65
52wk Low:21.95
Shares:55.25M
Float Shares:37.25M
Volume Ratio:0.81
T/O Rate:1.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.5172
EPS(LYR):-3.0510
ROE:-37.35%
ROA:-21.79%
PB:3.22
PE(LYR):-8.66

Loading ...

Switzerland's Pharvaris Q2 Loss Narrows, Cash Rises to €318 Mln

Reuters
·
Aug 12

Maze Therapeutics: Buy Rating Reaffirmed as Clinical De-Risking Supports Unchanged $110 Price Target

TIPRANKS
·
Aug 12

Maze Therapeutics Price Target Maintained with a $46.00/Share by BTIG

Dow Jones
·
Aug 12

Press Release: MindMaze Therapeutics Appoints Prof. John W. Krakauer as Strategic Advisor

Dow Jones
·
Aug 12

Maze Therapeutics Q2 EPS $(0.76) Misses $(0.73) Estimate

Benzinga Earnings
·
Aug 12

Earnings Flash (MAZE) Maze Therapeutics Posts Q2 Loss $0.76 per Share, vs. FactSet Est of $0.72 Loss

MT Newswires Live
·
Aug 12

Maze Therapeutics reports Q2 EPS (76c), consensus (70c)

TIPRANKS
·
Aug 12

Maze Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

Maze Therapeutics Rugi Bersih Q2 FY26 Melebar Ke USD 44,7 Juta; Rugi Per Saham Naik Ke USD 0,76

Reuters
·
Aug 12

Maze Therapeutics Inc Q2 Income from Operations USD -48.035 Million VS. Ibes Estimate USD -45.2 Million

THOMSON REUTERS
·
Aug 12

Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

GlobeNewswire
·
Aug 12

Press Release: MindMaze Therapeutics Completes Organizational Simplification and Provides Update on Neuro.io Equity Financing

Dow Jones
·
Aug 10

Maze Therapeutics CEO Jason V. Coloma Reports Sale of Common Shares Worth $921,153

Reuters
·
Aug 06

Maze Therapeutics CSBO Atul Dandekar Disposes of 7,500 Common Shares Worth $204,859.44

Reuters
·
Aug 01

Maze Therapeutics (MAZE) Stock Looks Fully Priced After A 59% Gain##

Simply Wall St.
·
Jul 17

Maze Therapeutics Advances MZE782 Phase 2 PKU Trial, Setting Up a New Catalyst for MAZE Investors

TIPRANKS
·
Jul 15

Maze Therapeutics CEO Jason V. Coloma Disposes of 34,501 Common Shares Worth $1.03 Million

Reuters
·
Jul 03

Maze Therapeutics CSBO Atul Dandekar Disposes of $210,150 in Common Shares

Reuters
·
Jul 02

Maze Therapeutics CEO Jason V. Coloma Sells USD 723,021 in Common Shares

Reuters
·
Jun 25

Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Maze Therapeutics, Inc. (MAZE) and Universal Health (UHS)

TIPRANKS
·
Jun 22